HD Hyundai Heavy Industries: Bleeds Under Strike, Production Disruptions Feared Despite Order BoomK-Corporate Analysis
Subscribe for your daily dose of unconventional business news 🚀
HD Hyundai Heavy Industries: Bleeds Under Strike, Production Disruptions Feared Despite Order Boom
Samjin Foods Expands Local Distribution with Grand Opening of 'Huadong 1st Store' in Shanghai's Prime Retail District
Efforts to Double High-Voltage Circuit Breaker Production by Hyosung Heavy Industries, Accelerating US Grid Market Penetration-5-800x600.webp)
Altheogen's US Patent Battle: 11 Claims Invalidated, Doubled Operating Profit Expected
HLB Innovation's Verismo Unveils Solid Tumor CAR-T Preclinical Data at SITC Conference
Small Insights Research: 'DiTech and LaserTech's Dramatic Profit Transformation'
Micron's Strike Woes: HBM's Core Facility at Risk of Ignition
Hyundai Motors bets 20 trillion won on India... Reorganize global production map with new plant in Pune
HLB Chairman's Personal Firm Buys Over 200,000 Additional Shares
Samsung Electronics Faces Fresh Pressure: Overseas Activists Demand ADR Issuance After Preferred Share Buyback
Roche Joins the Race with ALK7 Obesity Drug, Olikis Follows with OLX501A
HLB Panagene unveils PNA optimization technology at U.S. OTS… AOC platform development speed
D&D Pharmatech to Host ‘R&D Day 2026’ on Nov 3, Showcasing Core Pipeline Milestones and Global Strategy
HLB Rivoceranib (Ripiktu) Expands Prescription Base with U.S. NCCN Inclusion, Targets Tumor-Agnostic Label
Ollix plans to resubmit New Zealand clinical trial plan for macular degeneration treatment this month![[K Bio Global Phase 3 | [Plan 5] Mezzion takes on the first Fontan treatment... Turn clinical experience into commercialization competitiveness](https://media.markettimes.co.kr/file_000000009a3c8209814fd10b9cfba476-800x600.png)
[K Bio Global Phase 3 | [Plan 5] Mezzion takes on the first Fontan treatment... Turn clinical experience into commercialization competitiveness
HLB Biostep participates in AI national project worth 5 billion won... Expanding digital non-clinical CRO business
Hyundai Mobis lowers its performance expectations due to setbacks in finished vehicle production... A/S business is doing well
“Even 12 years in Yongin is not enough”… The reason why SK Hynix is rushing to the Honam plant
Olix rejects New Zealand clinical trial application for macular degeneration treatment… Promote resubmission after supplementation
Even if the state is shaken by patent disputes... Alteogen Keytruda SC, prescriptions surged 34% in September
HLB, visible right to 2 types of new anticancer drugs system in the US... Expectation of corporate value re-evaluation
HLB completes re-application to US FDA for new liver cancer drug... Overcoming manufacturing facility hurdles and retrying for approval
Submission of re-approval documents to FDA for first-line HLB liver cancer treatment (rivoceranib, camrelizumab combination therapy)
1,000 trillion won worth of money will be opened... Green transition led by POSCO, Hanwha, and LG
LG Ensol, double the operating profit forecast, ‘surprising performance’… Secured 240,000 tons of lithium in North America
MS releases large laptop running AI… Released on the 16th with NVIDIA chip
Samsung Electronics’ operating profit of 107 trillion won ‘new history’… Despite record-breaking performance, supply and demand pressures
Small Insight Research "Samki Energy Solutions – Beyond electric vehicles to AI data centers"
Hyundai Yacht, premium yacht discount of up to 8%... Winter promotion until December 20th